Revance Therapeutics Inc.

RVNC

Held by 5 specialist biotech funds

High Convergence

5 funds opened new positions. Next phase2 readout (RT001 (Botulinum Toxin Type A Topical Gel)): Apr 2009.

BiotechnologyCEO: Mark J. FoleyIPO: 2014Website ↗

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Catalysts

Phase 2Q1 2009RT001Lateral Canthal Lines, Crow's Feet, Facial WrinklesNCT00888914

Primary: The number of subjects classified as exhibiting improvement via the Investigator Global Assessment at Smile from Baseline (Day 0) to End of Study (Day 28) (Day 28)Enrollment:60/60Sites: 4RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2009RT001 (Botulinum Toxin Type A Topical Gel)Lateral Canthal LinesNCT00884234

Primary: The number of subjects classified as exhibiting improvement via the Investigator Global Assessment from Baseline (Day 0) to End of Study (Week 6). (Baseline (Day 0) and Week 6)Enrollment:30/30Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2009Botulinum Toxin Type ALateral Canthal Lines, Crow's Feet, Facial WrinklesNCT00968825

Primary: The number of subjects classified as exhibiting improvement via the Investigator Global Assessment of Lateral Canthal Line Severity at Rest from Baseline (Day 0) to Week 4; incidence of treatment emergent AEs (Week 4)Enrollment:73/73Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2009Botulinum Toxin Type ALateral Canthal Lines, Crow's Feet, Facial WrinklesNCT00968942

Primary: The number of subjects classified as exhibiting improvement via the Investigator Global Assessment of Lateral Canthal Line-Rest Severity Scale of the LCA at Baseline compared to Week 8; incidence of treatment emergent AEs (Week 8)Enrollment:36/36Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2009RT001Lateral Canthal LinesNCT00907387

Primary: The number of subjects classified as exhibiting improvement via the Investigator Global Assessment at Rest from Baseline (Day 0) to Day 28 (Day 28)Enrollment:72/72Sites: 9RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q3 2010RT001Lateral Canthal Lines, Crow's Feet, Facial WrinklesNCT01124565

Primary: Assessment of treatment-emergent adverse events based on safety assessments. (4 weeks and 8 weeks)Enrollment:40/40Sites: 3NA, TREATMENT

Phase 2Q3 2010RT001 Botulinum toxin type A (Dose A)Lateral Canthal Lines, Crow's Feet, Facial WrinklesNCT01124552

Primary: Subject improvement based in investigator assessment (Week 4)Enrollment:180/180Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q3 2010Botulinum Toxin Type ALateral Canthal Lines, Crow's Feet, Facial WrinklesNCT01064518

Primary: The number of subjects who show improvement based on the investigator global and patient assessments. (Week 4)Enrollment:90/90Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2013Botulinum Toxin Type ASkin AgingNCT01776606

Primary: Composite endpoint based upon the investigator global assessment and patient assessment of severity of lateral canthal lines (Week 4)Enrollment:247/247Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3NegativeQ3 2013Botulinum Toxin Type ASkin AgingNCT01818076

Primary: Incidences of treatment-emergent adverse events and serious treatment-emergent adverse events when the drug product is administered in repeated treatments (Up to 24 months)Enrollment:311/311Sites: 1NA, TREATMENT

Phase 2Q4 2013PlaceboSkin AgingNCT01940991

Primary: Composite endpoint (Week 4)Enrollment:82/82Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2015Botulinum Toxin Type AGlabellar Frown LinesNCT02303002

Primary: Proportion of subjects assessed as responders by investigator assessment of severity of glabellar lines at maximum frown (Week 24)Enrollment:268/268Sites: 1RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q4 2015Botulinum toxin type AHyperhidrosisNCT02565732

Primary: Hyperhidrosis Disease Severity Scale (HDSS) (Week 4)Enrollment:67/67Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2016DaxibotulinumtoxinATorticollis (Spasmodic)NCT02706795

Primary: Improvement of dystonia as measured by change from baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) - Total Score (Week 4)Enrollment:37/37Sites: 13TREATMENT

Phase 2NegativeQ2 2017daxibotulinumtoxin type APlantar FasciitisNCT02973269

Primary: Improvement in the American Orthopaedic Foot and Ankle Score (AOFAS) (16 weeks)Enrollment:7/7Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2017Botulinum Toxins, Type AGlabellar Frown LinesNCT03014635

Primary: Percentage of Subjects Who Achieved ≥ 2 Point Improvement Independently and Concurrently on Investigator and Patient Rating Scales (Week 4)Enrollment:306/306Sites: 14RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ4 2017Botulinum Toxins, Type AGlabellar Frown LinesNCT03014622

Primary: Percentage of Subjects Who Achieved ≥ 2 Point Improvement Independently and Concurrently on Investigator and Patient Rating Scales (Week 4)Enrollment:303/303Sites: 15RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q1 2018Botulinum Toxins, Type APlantar FasciitisNCT03137407

Primary: Change From Baseline at Week 8 in the Visual Analog Scale (VAS) for Pain for the Foot (Week 8)Enrollment:59/59Sites: 5RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ4 2018Botulinum Toxins, Type AGlabellar Frown LinesNCT03004248

Primary: Incidence of Treatment Emergent Adverse Events (TEAE) (0-36 weeks)Enrollment:2,691/2,691Sites: 61NA, TREATMENT

Phase 3PositiveQ4 2019DaxibotulinumtoxinA for injectionCervical DystoniaNCT03608397

Primary: Change from Baseline Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-total score (Week 4 and Week 6)Enrollment:301/301Sites: 75RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ1 2020DaxibotulinumtoxinA for injectionFrown LinesNCT03786770

Primary: Percentage of Participants With None or Mild in FHL Severity at Maximum Eyebrow Elevation (Week 4 After FHL Treatment)Enrollment:61/61Sites: 4NON_RANDOMIZED, TREATMENT

Phase 2PositiveQ2 2020DaxibotulinumtoxinA for injectionLateral Canthal LinesNCT03911102

Primary: Percentage of Participants With None or Mild in LCL Severity at Maximum Smile (Week 4 After LCL Treatment)Enrollment:63/63Sites: 4NON_RANDOMIZED, TREATMENT

Phase 2Q2 2020DAXI 80 UPlantar FasciitisNCT03825315

Primary: Change From Baseline at Week 8 in the Numeric Pain Rating Scale (NPRS) Score (Week 8)Enrollment:155/155Sites: 20RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ4 2020DaxibotulinumtoxinA for injectionUpper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines)NCT04259086

Primary: Percentage of Participants With None or Mild in GL Severity at Maximum Frown (Week 4)Enrollment:48/48Sites: 8NA, TREATMENT

Phase 2Q4 2020DAXI for injection 250 UUpper Limb SpasticityNCT03821402

Primary: Change From Baseline at Week 6 on the Modified Ashworth Scale (MAS) in the Suprahypertonic Muscle Group (SMG) Score (Week 6)Enrollment:83/83Sites: 26RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ2 2021daxibotulinumtoxinA for injectionCervical DystoniaNCT03617367

Primary: Long Term Safety of patients determined by the incidence of treatment-emergent adverse events (Up to 52 Weeks)Enrollment:357/357Sites: 65NA, TREATMENT

Phase 2Q4 2024DAXXIFYGlabellar Frown LinesNCT06411002

Revance Therapeutics Inc.

Signal Score

Fund Holdings

Position Trend

Catalysts

Position Details

Know which insider moves are real

Insider Signals

Also Held by These Funds

Research Links

Related Research